NIVO

Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023

Retrieved on: 
Thursday, May 25, 2023

The abstract was released by ASCO today and contains data available as of January 17, 2023.

Key Points: 
  • The abstract was released by ASCO today and contains data available as of January 17, 2023.
  • Batiraxcept plus cabo and nivo showed an ORR of 55% (n=11) in first-line treatment, consistent with combination first-line therapies.
  • In the batiraxcept monotherapy cohort (n=10), one patient attained stable disease, suggesting that batiraxcept achieves greatest activity in combination therapies, supporting the intended combination approach in the planned registrational Phase 3 trial.
  • Results showed no dose limiting toxicities at either dose of batiraxcept and demonstrated clinical activity of batiraxcept plus cabozantinib in patients with metastatic ccRCC.

Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting

Retrieved on: 
Wednesday, April 26, 2023

HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of a poster featuring batiraxcept data in clear cell renal cell carcinoma at the upcoming American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023 in Chicago, Illinois and virtually.

Key Points: 
  • HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of a poster featuring batiraxcept data in clear cell renal cell carcinoma at the upcoming American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023 in Chicago, Illinois and virtually.
  • In addition, an abstract highlighting batiraxcept data in pancreatic adenocarcinoma was accepted for publication.
  • Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)

MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting

Retrieved on: 
Tuesday, April 18, 2023

Allogeneic iNKTs, agenT-797, administered alone or in combination with anti-PD-1 therapy, shows activity in patients with refractory solid tumor cancers.

Key Points: 
  • Allogeneic iNKTs, agenT-797, administered alone or in combination with anti-PD-1 therapy, shows activity in patients with refractory solid tumor cancers.
  • AgenT-797 was administered without toxic lymphodepletion, persists for ~8 weeks, and appears to generate and drive immune cells into the tumor for destruction of cancer cells.
  • HC Wainwright to host KOL webcast with MiNK Therapeutics on Thursday, April 20th at 10:00am ET with Investigators Dr. Benedito Carneiro and Dr. Yelena Janjigian.
  • "Our pioneering off-the-shelf iNKT cell therapy, agenT-797, has demonstrated clinical benefit in solid tumor cancers, and we are committed to expediting its development.

MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Tuesday, March 21, 2023

NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the fourth quarter and full year 2022.

Key Points: 
  • NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the fourth quarter and full year 2022.
  • Fourth Quarter and Full Year 2022 Business Highlights:
    MiNK's focus is on advancing the clinical and preclinical programs of their iNKT cell pipeline, as well as expanding their in-house manufacturing capabilities.
  • MiNK is FDA cleared for fully in-house cGMP manufacturing of allogeneic iNKT cells, with a process designed to achieve > 5,000 doses per batch.
  • Cash used in operations for the year and fourth quarter ended December 31, 2022, was $18.9 million, and $4.4 million respectively, compared to $12.8 million and $1.7 million for the same periods in 2021.

CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 4, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today reported second quarter 2022 financial results and provided a business update.

Key Points: 
  • A data update for the fully enrolled squamous non-small cell lung cancer cohort is expected in the fourth quarter of 2022.
  • CytomX has prioritized the development of CX-2051 and an IND submission is planned in the second half of 2023.
  • General and administrative expenses increased by $2.4 million during the second quarter of 2022 to $11.7 million.
  • ET (2:00 p.m. PT) to discuss the financial results and provide a business update.